众生药业(002317) - 2017 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2017 was CNY 436,997,530.94, representing a 4.87% increase compared to CNY 416,722,374.18 in the same period last year[8] - Net profit attributable to shareholders was CNY 110,727,883.81, up 19.43% from CNY 92,712,574.07 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 107,217,194.82, reflecting a 16.52% increase from CNY 92,019,171.53 in the previous year[8] - Basic earnings per share increased by 7.69% to CNY 0.14 from CNY 0.13 in the previous year[8] - The company expects a net profit attributable to shareholders for the first half of 2017 to increase by 10.00% to 20.00%, ranging from CNY 24,526.39 million to CNY 26,756.06 million[20] Cash Flow - The net cash flow from operating activities decreased by 24.10%, amounting to CNY 129,504,542.64 compared to CNY 170,620,186.73 in the same period last year[8] - The net cash flow from investing activities decreased by 323.74% from CNY 60,181,792.18 to CNY -134,648,468.36, resulting from increased purchases of wealth management products[18] - The net cash flow from financing activities improved by 62.12% from CNY -112,063,496.79 to CNY -42,446,148.95, due to an increase in the amount of discounted bank acceptance bills maturing[18] - Cash and cash equivalents decreased by 140.10% from CNY 118,722,070.16 to CNY -47,609,172.32, attributed to increased purchases of wealth management products[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,304,247,997.65, a 1.87% increase from CNY 4,225,407,000.65 at the end of the previous year[8] - Net assets attributable to shareholders increased by 3.33% to CNY 3,507,805,192.75 from CNY 3,394,666,353.03 at the end of the previous year[8] - Short-term loans decreased by 58.70% from CNY 72,638,240.00 to CNY 30,000,000.00 due to the expiration of discounted bank acceptance bills[18] - Accounts payable increased by 77.97% from CNY 18,275,020.31 to CNY 32,523,392.14, attributed to a year-on-year increase in raw material purchases[18] - Employee compensation payable decreased by 41.42% from CNY 20,811,001.43 to CNY 12,190,728.72 due to year-end salary, vacation pay, and bonuses disbursed[18] Investment and Income - Investment income rose by 73.62% from CNY 1,988,328.77 to CNY 3,452,137.62, driven by increased returns from bank wealth management products[18] - Operating income from non-operating activities surged by 316.57% from CNY 1,068,182.89 to CNY 4,449,762.85, primarily due to increased government subsidies[18] - The company reported non-recurring gains of CNY 3,510,688.99, primarily from government subsidies[10] Shareholder Information - The total number of shareholders at the end of the reporting period was 33,227, with the largest shareholder holding 27.09% of the shares[12] Impairment and Returns - The weighted average return on equity decreased to 3.21% from 4.39% in the previous year, a decline of 1.18%[8] - The company reported a 293.50% increase in asset impairment losses from CNY 1,520,956.03 to CNY 5,985,010.38, due to an increase in bad debt provisions[18]